Do statins lower blood pressure?

Journal of Cardiovascular Pharmacology and Therapeutics

Volumn 12, Issue 2, 2007, Pages 112-123

  Mangat, Simardeep ^a   Agarwal, Sanjay ^a   Rosendorff, Clive ^a,b  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Blood pressure; Hypertension; Statins

Indexed keywords

ANGIOTENSIN II; ASCORBIC ACID; ATORVASTATIN; COLESTYRAMINE; COLLAGEN; ENALAPRIL; ENDOTHELIN 1; FIBRIN; FOSINOPRIL; GEMFIBROZIL; HYDROCHLOROTHIAZIDE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEVINOLIN; NITRIC OXIDE; PLACEBO; PRAVASTATIN; REACTIVE OXYGEN METABOLITE; SIMVASTATIN;

ARTERIOSCLEROSIS; ARTICLE; BLOOD PRESSURE REGULATION; CARDIOVASCULAR RISK; CELL PROLIFERATION; CHOLESTEROL SYNTHESIS; CLINICAL TRIAL; CROSS LINKING; DOWN REGULATION; DRUG EFFECT; DRUG MECHANISM; ENDOTHELIAL DYSFUNCTION; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; OXIDATIVE STRESS; PLEIOTROPY; PRIORITY JOURNAL; PROTEIN EXPRESSION; VASOCONSTRICTION; VASODILATATION;

ANIMALS; ANTILIPEMIC AGENTS; ARTERIOSCLEROSIS; BLOOD PRESSURE; CHOLESTEROL, LDL; CLINICAL TRIALS; ENDOTHELIUM, VASCULAR; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERCHOLESTEROLEMIA; HYPERTENSION;

EID: 34249748962     PISSN: 10742484     EISSN: None     Source Type: Journal    
DOI: 10.1177/1074248407300380     Document Type: Article

References (67)

1. Nissen SE, Nicholls SJ, Sipahi I., et al. ASTEROID Investigators. Effect of very high-intensity statin therapy on regression of coronary atherosclerosis. JAMA. 2006 ; 295: 1556-1565.
2. Schwartz GG, Olsson AG, Ezekowitz MD, et al. Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) Study Investigators. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial. JAMA. 2001 ; 285: 1711-1718.
3. Nishimura T., Faul JL, Berry GJ, et al. Simvastatin attenuates smooth muscle neointimal proliferation and pulmonary hypertension in rats. Am J Respir Crit Care Med. 2002 ; 166: 1403-1408.
4. John S., Schneider MP, Delles C., Jacobi J., Schmieder RE Lipid-independent effects of statins on endothelial function and bioavailability of nitric oxide in hypercholesterolemic patients. Am Heart J. 2005 ; 149: 473.
5. Steinberg D. Low density lipoprotein oxidation and its pathobiological significance. J Biol Chem 1997 ; 272: 20963-20966.
6. Ross R. Atherosclerosis-an inflammatory disease. N Engl J Med. 1999 ; 340: 115-126.
7. Podrez EA, Schmitt D., Hoff HF, Hazen SL Myeloperoxidasegenerated reactive nitrogen species convert LDL into an atherogenic form in vitro. J Clin Invest. 1999 ; 103: 1547-1560.
8. Zmijewski JW, Moellering DR, Le Goffe C, Landar A., Ramachandran A., Darley-Usmar VM Oxidized LDL induces mitochondrially associated reactive oxygen/ nitrogen species formation in endothelial cells. Am J Physiol Heart Circ Physiol. 2005 ; 289: H852 - H861.
9. Landmesser U., Dikalov S., Price SR, et al. Oxidation of tetrahydrobiopterin leads to uncoupling of endothelial cell nitric oxide synthase in hypertension. J Clin Invest. 2003 ; 111: 1201-1209.
10. Chin JH, Azhar S., Hoffman BB Inactivation of endothelial derived relaxing factor by oxidized lipoproteins. J Clin Invest. 1992 ; 89: 10-18.
11. Searles CD Transcriptional and posttranscriptional regulation of endothelial nitric oxide synthase expression. Am J Physiol Cell Physiol. 2006 ; 291: C803 - C816.
12. Boger RH, Sydow K., Borlak J., et al. LDL cholesterol upregulates synthesis of asymmetrical dimethylarginine in human endothelial cells: involvement of S-adenosylmethionine-dependent methyltransferases. Circ Res. 2000 ; 87: 99-105.
13. Chen LY, Mehta P., Mehta JL Oxidized LDL decreases L-arginine uptake and nitric oxide synthase protein expression in human platelets: relevance of the effect of oxidized LDL on platelet function. Circulation. 1996 ; 93: 1740-1746.
14. Rosendorff C., Hoffman Jie, Verrier E., Rouleau JR, Boerboom LE Cholesterol sensitizes coronary vessels to norepinephrine. Circulation Res 1981 ; 48: 320-329.
15. Nickenig G., Sachinidis A., Michaelsen F., et al. Upregulation of vascular angiotensin II receptor gene expression by low-density lipoprotein in vascular smooth muscle cells. Circulation. 1997 ; 95: 473-478.
16. Haug C., Schmid-Kotsas A., Zorn U., et al. Endothelin-1 synthesis and endothelin B receptor expression in human coronary artery smooth muscle cells and monocyte-derived macrophages is up-regulated by low density lipoproteins. J Mol Cell Cardiol. 2001 ; 33: 1701-1712.
17. Warnholtz A., Nickenig G., Schulz E., et al. Increased NADH-oxidase-mediated superoxide production in the early stages of atherosclerosis: evidence for involvement of the renin-angiotensin system. Circulation. 1999 ; 99: 2027-2033.
18. Cox DA, Cohen ML Effects of oxidized low-density lipoprotein on vascular contraction and relaxation: clinical and pharmacological implications in atherosclerosis. Pharmacol Rev. 1996 ; 48: 3-19.
19. Minor RL Jr, Myers PR, Bates JN, Harrison DG Diet-induced atherosclerosis increases the release of nitrogen oxides from rabbit aorta. J Clin Invest. 1990 ; 86: 2909-2116.
20. Panza JA, Quyyumi AA, Brush JE Jr, Epstein SE Abnormal endothelium-dependent vascular relaxation in patients with essential hypertension. N Engl J Med. 1990 ; 323: 22-27.
21. Casino PR, Kilcoyne CM, Quyyumi AA, Hoeg JM, Panza JA The role of nitric oxide in endothelium-dependent vasodilatation of hypercholesterolemic patients. Circulation. 1993 ; 88: 2541-2254.
22. Susic D., Varagic J., Ahn J., Slama M., Frohlich ED Beneficial pleiotropic vascular effects of rosuvastatin in two hypertensive models. J Am Coll Cardiol. 2003 ; 42: 1091-1097.
23. Wilson TW, Alonso-Galicia M., Roman RJ Effects of lipid-lowering agents in the Dahl salt-sensitive rat. Hypertension. 1998 ; 31: 225-231.
24. Jiang J., Roman RJ Lovastatin prevents development of hypertension in spontaneously hypertensive rats. Hypertension. 1997 ; 30: 968-974.
25. Goldstein JL, Brown MS Regulation of the mevalonate pathway. Nature. 1990 ; 343: 425-430.
26. Wassmann S., Laufs U., Baumer A., et al. HMG-CoA reductase inhibitors improve endothelial dysfunction in normocholesterolemic hypertension via reduced production of reactive oxygen species. Hypertension. 2001 ; 37: 1450-1457.
27. Takemoto M., Liao J. Pleiotropic effects of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors. Arterioscler Thromb Vasc Biol. 2001 ; 21: 1712-1719.
28. Laufs U, La Fata V, Plutzky J, Liao JK. Upregulation of endothelial nitric oxide synthase by HMG CoA reductase inhibitors. Circulation. 1998 ; 97: 1129-1135.
29. Wassmann S., Faul A., Hennen B., Scheller B., Bohm M., Nickenig G. Rapid effect of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibition on coronary endothelial function. Circ Res. 2003 ; 93: e98 - e103.
30. Laufs U., Liao JK Post-transcriptional regulation of endothelial nitric oxide synthase mRNA stability by Rho GTPase. J Biol Chem. 1998 ; 273: 24266-24271.
31. Everson WV, Smart EJ Influence of caveolin, cholesterol, and lipoproteins on nitric oxide synthase: implications for vascular disease. Trends Cardiovasc Med. 2001 ; 11: 246-250
32. Feron O., Dessy C., Moniotte S., Desager JP, Balligand JL Hypercholesterolemia decreases nitric oxide production by promoting the interaction of caveolin and endothelial nitric oxide synthase. J Clin Invest. 1999 ; 103: 897-905.
33. Feron O., Dessy C., Desager JP, Balligand JL Hydroxy-methylglutaryl- coenzyme A reductase inhibition promotes endothelial nitric oxide synthase activation through a decrease in caveolin abundance. Circulation. 2001 ; 103: 113-118.
34. Hernandez-Perera O., Perez-Sala D., Navarro-Antolin J., et al. Effects of the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors, atorvastatin and simvastatin, on the expression of endothelin-1 and endothelial nitric oxide synthase in vascular endothelial cells. J Clin Invest. 1998 ; 101: 2711-2719.
35. Dimmeler S., Aicher A., Vasa M. HMG-CoA reductase inhibitors (statins) increase endothelial progenitor cells via the PI 3-kinase/ Akt pathway. J Clin Invest. 2001 ; 108: 391-397.
36. Kuhlmann CR, Schafer M., Li F., et al. Modulation of endothelial Ca-activated K channels by oxidized LDL and its contribution to endothelial proliferation. Cardiovasc Res. 2003 ; 60: 626-634.
37. Wassmann S., Laufs U., Baumer AT, et al. Inhibition of geranylgeranylation reduces angiotensin II-mediated free radical production in vascular smooth muscle cells: involvement of angiotensin AT1 receptor expression and Rac1 GTPase. Mol Pharmacol. 2001 ; 59: 646-654.
38. Robinson JG, Smith B., Maheshwari N., Schrott H. Pleiotropic effects of statins: benefit beyond cholesterol reduction? A meta-regression analysis. J Am Coll Cardiol. 2005 ; 46: 1855-1862.
39. Gotto AM Jr. Review of primary and secondary prevention trials with lovastatin, pravastatin, and simvastatin. Am J Cardiol. 2005 ; 96: 34F - 38F.
40. Borghi C., Dormi A., Veronesi M., Sangiorgi Z., Gaddi A. Brisighella Heart Study Working Party. Association between different lipid-lowering treatment strategies and blood pressure control in the Brisighella Heart Study. Am Heart J. 2004 ; 148: 285-292.
41. Velussi M., Cernigoi AM, Tortul C., Merni M. Atorvastatin for the management of type 2 diabetic patients with dyslipidaemia. A mid-term (9 months) treatment experience. Diabetes Nutr Metab. 1999 ; 12: 407-412.
42. Borghi C., Prandin MG, Costa FV, Bacchelli S., Degli Esposti D., Ambrosioni E. Use of statins and blood pressure control in treated hypertensive patients with hypercholesterolemia. J Cardiovasc Pharmacol. 2000 ; 35: 549-555.
43. Sposito AC, Mansur AP, Coelho OR, Nicolau JC, Ramires JA Additional reduction in blood pressure after cholesterol-lowering treatment by statins (lovastatin or pravastatin) in hypercholesterolemic patients using angiotensin-converting enzyme inhibitors (enalapril or lisinopril). Am J Cardiol. 1999 ; 83: 1497-1499.
44. Kanbay M., Yildirir A., Bozbas H., et al. Statin therapy helps to control blood pressure levels in hypertensive, dyslipidemic patients. Renal Failure. 2005 ; 27: 297-303.
45. Magen E., Viskoper R., Mishal J., et al. Resistant arterial hypertension and hyperlipidemia: atorvastatin, not vitamin C, for blood pressure control. Isr Med Assoc J. 2004 ; 6: 742-746.
46. Nazzaro P., Manzari M., Merlo M., et al. Distinct and combined effects of ACE blockade and HMG-CoA reductase inhibition in hypertensive subjects. Hypertension. 1999 ; 33: 719-725.
47. Tonolo G., Melis MG, Formato M., et al. Additive effects of simvastatin beyond its effects on LDL cholesterol in hypertensive type 2 diabetic patients. Eur J Clin Invest. 2000 ; 11: 980-987.
48. Glorioso N., Troffa C., Filigheddu F., et al. Effect of the HMG-CoA reductase inhibitors on blood pressure in patients with essential hypertension and primary hypercholesterolemia. Hypertension. 1999 ; 34: 1281-1286.
49. Abetel G., Poget PN, Bonnabry JP Hypotensive effect of an inhibitor of cholesterol synthesis (fluvastatin): a pilot study 9 [in German]. Schweiz Med Wochenschr. 1998 ; 128: 272-277.
50. Ferrier KE, Muhlmann MH, Baguet JP, et al. Intensive cholesterol reduction lowers blood pressure and large artery stiffness in isolated systolic hypertension. J Am Coll Cardiol. 2002 ; 39: 1020-1025.
51. Terzoli L., Mircoli L., Raco R., Ferrari AU Lowering of elevated ambulatory blood pressure by HMG-CoA reductase inhibitors. J Cardio Pharm. 2005 ; 46: 310-315.
52. Sung BH, Izzo JL Jr, Wilson MF Effects of cholesterol reduction on BP response to mental stress in patients with high cholesterol. Am J Hypertens. 1997 ; 10: 592-599.
53. Leibovitz E., Hazanov N., Zimlichman R., Shargorodsky M., Gavish D. Treatment with atorvastatin improves small artery compliance in patients with severe hypercholesterolemia. Am J Hypertens 2001 ; 14: 1096-1098.
54. Straznicky NE, Howes LG, Lam W., Louis WJ Effects of pravastatin on cardiovascular reactivity to norepinephrine and angiotensin II in patients with hypercholesterolemia and systemic hypertension. Am J Cardiol. 1995 ; 75: 582-586.
55. Strazzullo P., Kerry SM, Barbato A., Versiero M., D'Elia L., Cappuccio FP Blood Pressure reduction with statins: a meta-analysis of randomized controlled trials. J Hypertens. 2006 ; 24 (suppl 4). S151.
56. Zanchetti A., Crepaldi G., Bond MG, et al. Systolic and pulse blood pressures (but not diastolic blood pressure and serum cholesterol) are associated with alterations in carotid intima-media thickness in the moderately hypercholesterolaemic hypertensive patients of the Plaque Hypertension Lipid Lowering Italian Study. PHYLLIS study group. J Hypertens. 2001 ; 19: 79-88.
57. D'Agostino RB, Kannel WB, Stepanians MN, D'Agostino LC Efficacy and tolerability of lovastatin in hypercholesterolemia in patients with systemic hypertension. Am J Cardiol. 1993 ; 71: 82-87.
58. Hodis HN, Mack WJ, LaBree L., et al. Reduction in carotid arterial wall thickness using lovastatin and dietary therapy: a randomized controlled clinical trial. Ann Intern Med. 1996 ; 124: 548-556.
59. Ichihara A., Hayashi M., Koura Y., Tada Y., Kaneshiro Y., Saruta T. Long-term effects of statins on arterial pressure and stiffness of hypertensives. J Hum Hypertens. 2005 ; 19: 103-109.
60. Koh KK, Quon MJ, Han SH, et al. Additive beneficial effects of losartan combined with simvastatin in the treatment of hypercholesterolemic, hypertensive patients. Circulation. 2004 ; 110: 3687-3692.
61. O'Callaghan CJ, Krum H., Conway EL, et al. Short-term effects of pravastatin on blood pressure in hypercholesterolemic hypertensive patients. Blood Press. 1994 ; 3: 404-406.
62. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet. 2002 ; 360: 7-22.
63. Colhoun HM, Betteridge DJ, Durrington PN, et al. CARDS investigators. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet. 2004 ; 364: 685-696.
64. van Etten RW, de Koning EJ, Honing ML, Stroes ES, Gaillard CA, Rabelink TJ Intensive lipid lowering by statin therapy does not improve vasoreactivity in patients with type 2 diabetes. Arterioscler Thromb Vasc Biol. 2002 ; 22: 799-804.
65. Antonicelli R., Onorato G., Pagelli P., Pierazzoli L., Paciaroni E. Simvastatin in the treatment of hypercholesterolemia in elderly patients. Clin Ther. 1990 ; 12: 165-171.
66. Sartor G., Katzman P., Eizyk E., et al. Simvastatin treatment of hypercholesterolemia in patients with insulin dependent diabetes mellitus. Int J Clin Pharmacol Ther. 1995 ; 33: 3-6.
67. Muramatsu J., Kobayashi A., Hasegawa N., Yokouchi S. Hemodynamic changes associated with reduction in total cholesterol by treatment with the HMG-CoA reductase inhibitor pravastatin. Atherosclerosis. 1997 ; 130: 179-182.